注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
SQZ Biotechnologies Co是一家临床阶段的生物技术公司,专注于释放细胞疗法的全部潜力,使患有癌症、自身免疫性疾病和传染病以及其他严重疾病的患者受益。在肿瘤学领域,它正在开发基于通过工程化抗原呈递引导肿瘤抗原特异性免疫激活的细胞治疗平台。它在其SQZ抗原呈递细胞(APC)、SQZ增强型APC(eAPC)和SQZ激活抗原载体(AAC)细胞治疗平台拥有三个肿瘤候选药物。在其自身免疫性疾病产品组合中,该公司正在开发其SQZ耐受抗原载体(TAC)细胞治疗平台,以恢复对自身抗原或其他自身免疫性疾病相关抗原的免疫耐受性。这些抗原是疾病发病机制的核心。APC平台主要产生CD8+ T细胞反应。SQZAPC通过对患者自身外周血单个核细胞进行体外工程改造而成。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Bernard Coulie | 56 | 2021 | Independent Chairman |
Robert S. Langer | 75 | - | Co-Founder & Member of Scientific Advisory Board |
Howard Bernstein | 67 | 2015 | Interim CEO & Director |
Klavs F. Jensen | 71 | 2013 | Independent Director |
Amy W. Schulman | 63 | 2015 | Director |
Ulrich von Andrian | - | - | Member of Scientific Advisory Board |
Darrell J. Irvine | - | - | Member of Scientific Advisory Board |
Arlene Sharpe | - | - | Member of Scientific Advisory Board |
Sapna Srivastava | 53 | 2020 | Independent Director |
Marc Schegerin | 48 | 2020 | Independent Director |
Tyler E. Jacks | 63 | - | Member of Scientific Advisory Board |
Kai W. Wucherpfennig | - | 2020 | Member of Scientific Advisory Board |
David H. Sachs | 82 | - | Member of Scientific Advisory Board |
Mark Shlomchik | - | - | Member of Scientific Advisory Board |
Marc William Elia | 48 | 2018 | Independent Director |
Pushkal P. Garg | 56 | 2018 | Independent Director |
Patrick V. J. J. Vink | 61 | 2021 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核